Evaluating treatment of hepatitis C for hemolytic anemia management.
DebRoy
Swati
S
Department of Mathematics, University of Florida, Gainesville, FL, USA. swati@math.ufl.edu
Kribs-Zaleta
Christopher
C
Mubayi
Anuj
A
Cardona-Meléndez
Gloriell M
GM
Medina-Rios
Liana
L
Kang
MinJun
M
Diaz
Edgar
E
D000743:Anemia, Hemolytic / Q000139:chemically induced / Q000517:prevention & control*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D003198:Computer Simulation; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000627:therapeutic use*; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects*; D008954:Models, Biological; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*
D000998:Antiviral Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D012254:Ribavirin; D007372:Interferons